



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

23 October 2023  
EMA/PRAC/434138/2023 Corr<sup>1</sup>  
Human Medicines Division

## Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 23-26 October 2023

Chair: Sabine Straus – Vice-Chair: Martin Huber

23 October 2023, 10:30 – 19:45, via teleconference

24 October 2023, 08:30 – 19:45, via teleconference

25 October 2023, 08:30 – 19:45, via teleconference

26 October 2023, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)

09 November 2023, 09:00 – 12:00, via teleconference

### Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

### Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents ([EMA/127362/2006 Rev.1](#)).

---

<sup>1</sup> 26 October 2023 - Bupivacaine, meloxicam - ZYNRELEF - PSUSA/00010880/202303 – update of action



## Table of contents

<b>1.</b>	<b>Introduction</b>	<b>10</b>
1.1.	Welcome and declarations of interest of members, alternates and experts.....	10
1.2.	Agenda of the meeting on 23-26 October 2023 .....	10
1.3.	Minutes of the previous meeting on 25-28 September 2023.....	10
<b>2.</b>	<b>EU referral procedures for safety reasons: urgent EU procedures</b>	<b>10</b>
2.1.	Newly triggered procedures .....	10
2.2.	Ongoing procedures .....	10
2.3.	Procedures for finalisation.....	10
<b>3.</b>	<b>EU referral procedures for safety reasons: other EU referral procedures</b>	<b>10</b>
3.1.	Newly triggered procedures .....	10
3.2.	Ongoing procedures .....	11
3.3.	Procedures for finalisation.....	11
3.4.	Re-examination procedures.....	11
3.5.	Others .....	11
<b>4.</b>	<b>Signals assessment and prioritisation</b>	<b>11</b>
4.1.	New signals detected from EU spontaneous reporting systems.....	11
4.1.1.	Elasomeran - SPIKEVAX (CAP) .....	11
4.1.2.	Esomeprazole - NEXIUM CONTROL (CAP); NAP.....	11
4.1.3.	Osimertinib – TAGRISSO (CAP) .....	12
4.1.4.	Tozinameran - COMIRNATY (CAP).....	12
4.2.	New signals detected from other sources.....	12
4.3.	Signals follow-up and prioritisation.....	12
4.3.1.	Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/SDA/006 .....	12
4.3.2.	Dapagliflozin – EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/015, FORXIGA (CAP) - EMEA/H/C/002322/SDA/028, EBYMECT (CAP) - EMEA/H/C/004162/SDA/014, XIGDUO (CAP) - EMEA/H/C/002672/SDA/017, QTERN (CAP) - EMEA/H/C/004057/SDA/009 .....	12
4.3.3.	Glucagon-like peptide-1 (GLP-1) receptor agonists: dulaglutide – TRULICITY (CAP) - EMEA/H/C/002825/SDA/014; exenatide – BYDUREON (CAP) - EMEA/H/C/002020/SDA/029, BYETTA (CAP) - EMEA/H/C/000698/SDA/049; insulin degludec, liraglutide – XULTOPHY (CAP) - EMEA/H/C/002647/SDA/005; liraglutide – SAXENDA (CAP) - EMEA/H/C/003780/SDA/019, VICTOZA (CAP) - EMEA/H/C/001026/SDA/039; insulin glargine, lixisenatide – SULIQUA (CAP) - EMEA/H/C/004243/SDA/008; lixisenatide – LYXUMIA (CAP) - EMEA/H/C/002445/SDA/016; semaglutide – OZEMPIC (CAP) - EMEA/H/C/004174/SDA/007, RYBELSUS (CAP) - EMEA/H/C/004953/SDA/012, WEGOVY (CAP) - EMEA/H/C/005422/SDA/006 .....	13
4.4.	Variation procedure(s) resulting from signal evaluation .....	13

## 5. Risk management plans (RMPs) 13

<b>5.1. Medicines in the pre-authorisation phase</b>	<b>13</b>
5.1.1. Bevacizumab - EMEA/H/C/005723	13
5.1.2. Catumaxomab - EMEA/H/C/005697	13
5.1.3. Cefepime, enmetazobactam - EMEA/H/C/005431	13
5.1.4. Danicopan - EMEA/H/C/005517, PRIME, Orphan	14
5.1.5. Influenza vaccine (H5N1) - EMEA/H/C/006052	14
5.1.6. Influenza vaccine (H5N1) - EMEA/H/C/006051	14
5.1.7. Lecanemab - EMEA/H/C/005966	14
5.1.8. Paliperidone - EMEA/H/C/006185	14
5.1.9. Polihexanide - EMEA/H/C/005858, Orphan	14
5.1.10. Pomalidomide - EMEA/H/C/006195	15
<b>5.2. Medicines in the post-authorisation phase – PRAC-led procedures</b>	<b>15</b>
5.2.1. Dexamethasone - OZURDEX (CAP) - EMEA/H/C/001140/II/0044	15
5.2.2. Emtricitabine, tenofovir disoproxil - EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004137/WS2486/0025	15
5.2.3. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2515/0018; VIMPAT (CAP) - EMEA/H/C/000863/WS2515/0100	15
5.2.4. Lenvatinib - LENVIMA (CAP) - EMEA/H/C/003727/II/0053	15
5.2.5. Tixagevimab, cilgavimab - EVUSHELD (CAP) - EMEA/H/C/005788/II/0013	16
5.2.6. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/II/0054	16
<b>5.3. Medicines in the post-authorisation phase – CHMP-led procedures</b>	<b>16</b>
5.3.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0095	16
5.3.2. Aripiprazole - ABILIFY MAINTENA (CAP) - EMEA/H/C/002755/X/0045	16
5.3.3. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/II/0023, Orphan	17
5.3.4. Azacitidine - AZACITIDINE ACCORD (CAP) - EMEA/H/C/005147/X/0013	17
5.3.5. Bempedoic acid - NILEMDO (CAP) - EMEA/H/C/004958/II/0031	17
5.3.6. Bempedoic acid, ezetimibe - NUSTENDI (CAP) - EMEA/H/C/004959/II/0035	17
5.3.7. Budesonide, formoterol fumarate dihydrate - BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. (CAP) - EMEA/H/C/004882/II/0012/G	18
5.3.8. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/II/0034	18
5.3.9. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/X/0033	18
5.3.10. Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID (CAP) - EMEA/H/C/002246/II/0058	19
5.3.11. Dabigatran etexilate - PRADAXA (CAP) - EMEA/H/C/000829/II/0147/G	19
5.3.12. Denosumab - PROLIA (CAP) - EMEA/H/C/001120/II/0099	19
5.3.13. Faricimab - VABYSMO (CAP) - EMEA/H/C/005642/II/0005	20
5.3.14. Hydroxycarbamide - XROMI (CAP) - EMEA/H/C/004837/II/0019	20
5.3.15. Idecabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0031, Orphan	20
5.3.16. Infliximab - REMSIMA (CAP) - EMEA/H/C/002576/II/0133/G	21

5.3.17.	Influenza vaccine (surface antigen, inactivated, adjuvanted) - FLUAD TETRA (CAP) - EMEA/H/C/004993/II/0043.....	21
5.3.18.	Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/II/0080.....	22
5.3.19.	Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0039 .....	22
5.3.20.	Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136.....	22
5.3.21.	Opicapone - ONGENTYS (CAP) - EMEA/H/C/002790/WS2552/0060; ONTILYV (CAP) - EMEA/H/C/005782/WS2552/0015 .....	23
5.3.22.	Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/X/0031/G .....	23
5.3.23.	Pegcetacoplan - ASPAVELI (CAP) - EMEA/H/C/005553/II/0011, Orphan .....	23
5.3.24.	Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0138.....	24
5.3.25.	Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/II/0012 .....	24
5.3.26.	Saxagliptin - ONGLYZA (CAP) - EMEA/H/C/001039/II/0057 .....	24
5.3.27.	Selexipag - UPTRAVI (CAP) - EMEA/H/C/003774/X/0038 .....	25
5.3.28.	Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0021.....	25
5.3.29.	Selpercatinib - RETSEVMO (CAP) - EMEA/H/C/005375/II/0022.....	25
5.3.30.	Sotorasib - LUMYKRAS (CAP) - EMEA/H/C/005522/II/0007 .....	25
5.3.31.	Spesolimab - SPEVIGO (CAP) - EMEA/H/C/005874/X/0006/G.....	26
5.3.32.	Tisagenlecleucel - KYMTRIAH (CAP) - EMEA/H/C/004090/II/0075, Orphan .....	26
5.3.33.	Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0188/G.....	27

## **6. Periodic safety update reports (PSURs) 27**

<b>6.1.</b>	<b>PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only .....</b>	<b>27</b>
6.1.1.	Avacopan - TAVNEOS (CAP) - PSUSA/00010967/202303.....	27
6.1.2.	Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202303 .....	27
6.1.3.	Betaine anhydrous - CYSTADANE (CAP) - PSUSA/00000390/202302.....	27
6.1.4.	Bupivacaine, meloxicam - ZYNRELEF - PSUSA/00010880/202303.....	28
6.1.5.	Cabotegravir - VOCABRIA (CAP) - PSUSA/00010900/202303 .....	28
6.1.6.	Cenobamate - ONTOZRY (CAP) - PSUSA/00010921/202303.....	28
6.1.7.	Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202303 .....	28
6.1.8.	Ciclosporin - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202303 .....	28
6.1.9.	Dabigatran - PRADAXA (CAP) - PSUSA/00000918/202303 .....	29
6.1.10.	Dimethyl fumarate - SKILARENCE (CAP) - PSUSA/00010647/202303.....	29
6.1.11.	Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202303 .....	29
6.1.12.	Duvelisib - COPIKTRA (CAP) - PSUSA/00010939/202303.....	29
6.1.13.	Eftrenonacog alfa - ALPROLIX (CAP) - PSUSA/00010499/202303.....	29
6.1.14.	Filgotinib - JYSELECA (CAP) - PSUSA/00010879/202303 .....	29
6.1.15.	Fingolimod - GILENYA (CAP) - PSUSA/00001393/202302 .....	30
6.1.16.	Gozetotide - LOCAMETZ (CAP) - PSUSA/00011030/202303.....	30
6.1.17.	Ibritumomab tiuxetan - ZEVALIN (CAP) - PSUSA/00001704/202302.....	30

6.1.18.	Idecabtagene vicleucel - ABECMA (CAP) - PSUSA/00010954/202303 .....	30
6.1.19.	Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202304 .....	30
6.1.20.	Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202303 .....	31
6.1.21.	Lutetium ( <sup>177</sup> Lu) vipivotide tetraxetan - PLUVICTO (CAP) - PSUSA/00011031/202303.....	31
6.1.22.	Maralixibat - LIVMARLI (CAP) - PSUSA/00011032/202303 .....	31
6.1.23.	Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202303 .....	31
6.1.24.	Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202303 .....	31
6.1.25.	Niraparib - ZEJULA (CAP) - PSUSA/00010655/202303.....	31
6.1.26.	Nivolumab, relatlimab - OPDUALAG (CAP) - PSUSA/00011018/202303.....	32
6.1.27.	Ofatumumab - KESIMPTA (CAP) - PSUSA/00010927/202303 .....	32
6.1.28.	Olipudase alfa - XENPOZYME (CAP) - PSUSA/00011003/202303.....	32
6.1.29.	Oritavancin - TENKASI (CAP) - PSUSA/00010368/202303 .....	32
6.1.30.	Ponesimod - PONVORY (CAP) - PSUSA/00010940/202303 .....	32
6.1.31.	Rilpivirine - REKAMBYS (CAP) - PSUSA/00010901/202303.....	32
6.1.32.	Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202303.....	33
6.1.33.	Selinexor - NEXPOVIO (CAP) - PSUSA/00010926/202303 .....	33
6.1.34.	Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202304.....	33
6.1.35.	Siponimod - MAYZENT (CAP) - PSUSA/00010818/202303.....	33
6.1.36.	Solriamfetol - SUNOSI (CAP) - PSUSA/00010831/202303.....	33
6.1.37.	Tebentafusp - KIMMTRAK (CAP) - PSUSA/00010991/202303 .....	34
6.1.38.	Tepotinib - TEPMETKO (CAP) - PSUSA/00010979/202303.....	34
6.1.39.	Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202303.....	34
6.1.40.	Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202303 .....	34
6.1.41.	Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202303 .....	34
<b>6.2.</b>	<b>PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) .....</b>	<b>35</b>
6.2.1.	Pramipexole - MIRAPEXIN (CAP); SIFROL (CAP); NAP - PSUSA/00002491/202304 .....	35
6.2.2.	Timolol, travoprost - DUOTRAV (CAP); NAP - PSUSA/00002962/202302.....	35
<b>6.3.</b>	<b>PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only .....</b>	<b>35</b>
6.3.1.	BCG (bacillus calmette-guérin) for Immunotherapy (NAP) - PSUSA/00000303/202303.....	35
6.3.2.	BCG vaccine (freeze-dried) (NAP) - PSUSA/00000304/202303 .....	35
6.3.3.	Bicalutamide (NAP) - PSUSA/00000407/202302 .....	35
6.3.4.	Dienogest, ethinylestradiol (NAP) - PSUSA/00001057/202303.....	36
6.3.5.	Ethosuximide (NAP) - PSUSA/00001316/202303 .....	36
6.3.6.	Fluconazole (NAP) - PSUSA/00001404/202303.....	36
6.3.7.	Furosemide, spironolactone (NAP) - PSUSA/00001493/202303 .....	36
6.3.8.	Human plasma (NAP) - PSUSA/00001635/202302 .....	36
6.3.9.	Oxycodone (NAP) - PSUSA/00002254/202304 .....	36

<b>6.4.</b>	<b>Follow-up to PSUR/PSUSA procedures .....</b>	<b>37</b>
6.4.1.	Venetoclax - VENClyxto (CAP) - EMEA/H/C/004106/LEG 017.2.....	37
<b>6.5.</b>	<b>Variation procedure(s) resulting from PSUSA evaluation .....</b>	<b>37</b>
6.5.1.	Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0243.....	37
6.5.2.	Laronidase - ALDURAZYME (CAP) - EMEA/H/C/000477/II/0085 .....	37
<b>6.6.</b>	<b>Expedited summary safety reviews .....</b>	<b>38</b>
<b>7.</b>	<b>Post-authorisation safety studies (PASS) .....</b>	<b>38</b>
<b>7.1.</b>	<b>Protocols of PASS imposed in the marketing authorisation(s).....</b>	<b>38</b>
7.1.1.	Alemtuzumab - Lemtrada (CAP) - EMEA/H/C/PSA/S/0107.....	38
7.1.2.	Valproate (NAP) - EMEA/H/N/PSP/J/0075.13 .....	38
<b>7.2.</b>	<b>Protocols of PASS non-imposed in the marketing authorisation(s) .....</b>	<b>38</b>
7.2.1.	Avatrombopag - DOPTeLET (CAP) - EMEA/H/C/004722/MEA 003.4 .....	38
7.2.2.	Cannabidiol - EPIDYOLEX (CAP) - EMEA/H/C/004675/MEA 007.3 .....	39
7.2.3.	Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 008.....	39
7.2.4.	Coronavirus (COVID-19) vaccine (recombinant protein receptor binding domain fusion heterodimer) - BIMERVAX (CAP) - EMEA/H/C/006058/MEA 009.....	39
7.2.5.	Ivosidenib - TIBSOVO (CAP) - EMEA/H/C/005936/MEA 003 .....	39
7.2.6.	Linaclootide - CONSTELLA (CAP) - EMEA/H/C/002490/MEA 009.7.....	40
7.2.7.	Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 001 .....	40
7.2.8.	Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 002 .....	40
7.2.9.	Romozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.7 .....	41
7.2.10.	Romozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.7 .....	41
7.2.11.	Romozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.5 .....	41
7.2.12.	Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 002.1.....	41
7.2.13.	Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 005.1.....	42
7.2.14.	Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 037.5 .....	42
7.2.15.	Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 017.1 .....	42
7.2.16.	Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 044.17 .....	42
7.2.17.	Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/MEA 005.1 .....	43
7.2.18.	Voclosporin - LUPKYNIS (CAP) - EMEA/H/C/005256/MEA 002.1 .....	43
<b>7.3.</b>	<b>Results of PASS imposed in the marketing authorisation(s).....</b>	<b>43</b>
7.3.1.	Valproate (NAP) - EMEA/H/N/PSR/J/0043 .....	43
7.3.2.	Valproate (NAP) - EMEA/H/N/PSR/J/0045 .....	43
<b>7.4.</b>	<b>Results of PASS non-imposed in the marketing authorisation(s).....</b>	<b>44</b>
7.4.1.	Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0093.....	44
7.4.2.	Belimumab - BENLYSTA (CAP) - EMEA/H/C/002015/II/0116 .....	44
7.4.3.	Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0082 .....	44
7.4.4.	Elasomeran - SPIKEVAX (CAP) - EMEA/H/C/005791/II/0110 .....	45

7.4.5.	Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/WS2519/0071/G; MODIGRAF (CAP) - EMEA/H/C/000954/WS2519/0046/G .....	45
<b>7.5.</b>	<b>Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation.....</b>	<b>45</b>
7.5.1.	Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/SOB 009.1 .....	45
7.5.2.	Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/ANX 002.6 .....	46
7.5.3.	Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 005.....	46
7.5.4.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.9 .....	46
7.5.5.	Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 002 .....	46
7.5.6.	Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 003 .....	46
7.5.7.	Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 004 .....	47
7.5.8.	Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/MEA 006.6 .....	47
7.5.9.	Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) - EMEA/H/C/003687/MEA 003.15 .....	47
<b>7.6.</b>	<b>Others .....</b>	<b>47</b>
<b>7.7.</b>	<b>New Scientific Advice .....</b>	<b>47</b>
<b>7.8.</b>	<b>Ongoing Scientific Advice .....</b>	<b>48</b>
<b>7.9.</b>	<b>Final Scientific Advice (Reports and Scientific Advice letters) .....</b>	<b>48</b>
<b>8.</b>	<b>Renewals of the marketing authorisation, conditional renewal and annual reassessments</b>	<b>48</b>
<b>8.1.</b>	<b>Annual reassessments of the marketing authorisation .....</b>	<b>48</b>
8.1.1.	Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0062 (without RMP).....	48
8.1.2.	Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0036 (without RMP) .....	48
<b>8.2.</b>	<b>Conditional renewals of the marketing authorisation .....</b>	<b>48</b>
<b>8.3.</b>	<b>Renewals of the marketing authorisation .....</b>	<b>48</b>
8.3.1.	Lusutrombopag - MULPLEO (CAP) - EMEA/H/C/004720/R/0018 (without RMP) .....	48
8.3.2.	Paclitaxel - PAZENIR (CAP) - EMEA/H/C/004441/R/0015 (with RMP).....	49
8.3.3.	Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP) .....	49
8.3.4.	Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/R/0039 (without RMP) .....	49
8.3.5.	Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/R/0019 (without RMP) .....	49
8.3.6.	Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/R/0017 (without RMP) .....	49
<b>9.</b>	<b>Product related pharmacovigilance inspections</b>	<b>49</b>
<b>9.1.</b>	<b>List of planned pharmacovigilance inspections.....</b>	<b>49</b>
<b>9.2.</b>	<b>Ongoing or concluded pharmacovigilance inspections.....</b>	<b>50</b>
<b>9.3.</b>	<b>Others .....</b>	<b>50</b>
<b>10.</b>	<b>Other safety issues for discussion requested by the CHMP or the EMA</b>	<b>50</b>
<b>10.1.</b>	<b>Safety related variations of the marketing authorisation.....</b>	<b>50</b>

<b>10.2.</b>	<b>Timing and message content in relation to Member States' safety announcements</b>	<b>50</b>
<b>10.3.</b>	<b>Other requests</b>	<b>50</b>
<b>10.4.</b>	<b>Scientific Advice</b>	<b>50</b>
<b>11.</b>	<b>Other safety issues for discussion requested by the Member States</b>	<b>50</b>
<b>11.1.</b>	<b>Safety related variations of the marketing authorisation</b>	<b>50</b>
11.1.1.	Hydroxyethyl starch (NAP) - DE/H/xxxx/WS/1360, DE/H/xxxx/WS/1452	50
<b>11.2.</b>	<b>Other requests</b>	<b>51</b>
<b>12.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>51</b>
<b>12.1.</b>	<b>Mandate and organisation of the PRAC</b>	<b>51</b>
12.1.1.	PRAC membership	51
12.1.2.	Vote by proxy	51
<b>12.2.</b>	<b>Coordination with EMA Scientific Committees or CMDh-v</b>	<b>51</b>
<b>12.3.</b>	<b>Coordination with EMA Working Parties/Working Groups/Drafting Groups</b>	<b>51</b>
<b>12.4.</b>	<b>Cooperation within the EU regulatory network</b>	<b>51</b>
12.4.1.	Health threats and EMA Emergency Task Force (ETF) activities - update	51
12.4.2.	PRAC strategic review and learning meeting (SRLM) under the Spanish presidency of the European Union (EU) Council – Madrid, Spain, 14 - 15 November 2023 - agenda	51
<b>12.5.</b>	<b>Cooperation with International Regulators</b>	<b>52</b>
<b>12.6.</b>	<b>Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee</b>	<b>52</b>
<b>12.7.</b>	<b>PRAC work plan</b>	<b>52</b>
<b>12.8.</b>	<b>Planning and reporting</b>	<b>52</b>
12.8.1.	EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q3 2023 and predictions	52
12.8.2.	PRAC workload statistics – Q3 2023	52
<b>12.9.</b>	<b>Pharmacovigilance audits and inspections</b>	<b>52</b>
12.9.1.	Pharmacovigilance systems and their quality systems	52
12.9.2.	Pharmacovigilance inspections	52
12.9.3.	Pharmacovigilance audits	52
<b>12.10.</b>	<b>Periodic safety update reports (PSURs) &amp; Union reference date (EURD) list</b>	<b>52</b>
12.10.1.	Periodic safety update reports	52
12.10.2.	Granularity and Periodicity Advisory Group (GPAG)	53
12.10.3.	PSURs repository	53
12.10.4.	Union reference date list – consultation on the draft list	53
12.10.5.	Periodic safety update reports single assessment (PSUSA) – review of 'other considerations' section in the assessment report – update and proposed way forward	53
<b>12.11.</b>	<b>Signal management</b>	<b>53</b>
12.11.1.	Signal management – feedback from Signal Management Review Technical (SMART) Working Group	53



<b>12.12.</b>	<b>Adverse drug reactions reporting and additional reporting .....</b>	<b>53</b>
12.12.1.	Management and reporting of adverse reactions to medicinal products.....	53
12.12.2.	Additional monitoring .....	53
12.12.3.	List of products under additional monitoring – consultation on the draft list .....	53
<b>12.13.</b>	<b>EudraVigilance database .....</b>	<b>54</b>
12.13.1.	Activities related to the confirmation of full functionality .....	54
<b>12.14.</b>	<b>Risk management plans and effectiveness of risk minimisations .....</b>	<b>54</b>
12.14.1.	Risk management systems .....	54
12.14.2.	Tools, educational materials and effectiveness measurement of risk minimisations .....	54
<b>12.15.</b>	<b>Post-authorisation safety studies (PASS) .....</b>	<b>54</b>
12.15.1.	Post-authorisation Safety Studies – imposed PASS .....	54
12.15.2.	Post-authorisation Safety Studies – non-imposed PASS .....	54
<b>12.16.</b>	<b>Community procedures.....</b>	<b>54</b>
12.16.1.	Referral procedures for safety reasons .....	54
<b>12.17.</b>	<b>Renewals, conditional renewals, annual reassessments.....</b>	<b>54</b>
<b>12.18.</b>	<b>Risk communication and transparency .....</b>	<b>54</b>
12.18.1.	Public participation in pharmacovigilance.....	54
12.18.2.	Safety communication.....	55
<b>12.19.</b>	<b>Continuous pharmacovigilance .....</b>	<b>55</b>
12.19.1.	Incident management .....	55
<b>12.20.</b>	<b>Impact of pharmacovigilance activities .....</b>	<b>55</b>
<b>12.21.</b>	<b>Others .....</b>	<b>55</b>
12.21.1.	Good Pharmacovigilance Practice (GVP) – end-of-year update for 2023 and planning for 2024 .....	55
12.21.2.	Presentation of draft reflection paper on ‘Use of real-world data to generate real-world evidence in non-interventional studies’.....	55
<b>13.</b>	<b>Any other business</b>	<b>55</b>
<b>14.</b>	<b>Explanatory notes</b>	<b>56</b>

## **1. Introduction**

### **1.1. Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 23-26 October 2023. See November 2023 PRAC minutes (to be published post December 2023 PRAC meeting).

### **1.2. Agenda of the meeting on 23-26 October 2023**

**Action:** For adoption

### **1.3. Minutes of the previous meeting on 25-28 September 2023**

**Action:** For adoption

## **2. EU referral procedures for safety reasons: urgent EU procedures**

### **2.1. Newly triggered procedures**

None

### **2.2. Ongoing procedures**

None

### **2.3. Procedures for finalisation**

None

## **3. EU referral procedures for safety reasons: other EU referral procedures**

### **3.1. Newly triggered procedures**

None

### 3.2. Ongoing procedures

None

### 3.3. Procedures for finalisation

None

### 3.4. Re-examination procedures<sup>2</sup>

None

### 3.5. Others

None

## 4. Signals assessment and prioritisation<sup>3</sup>

### 4.1. New signals detected from EU spontaneous reporting systems

#### 4.1.1. Elasomeran - SPIKEVAX (CAP)

---

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Signal of postmenopausal haemorrhage

**Action:** For adoption of PRAC recommendation

EPITT 20015 – New signal

Lead Member State(s): DK

#### 4.1.2. Esomeprazole - NEXIUM CONTROL (CAP); NAP

---

Applicant: GlaxoSmithKline Dungarvan Ltd (Nexium Control), various

PRAC Rapporteur: Rugile Pilviniene

Scope: Signal of Erectile dysfunction

**Action:** For adoption of PRAC recommendation

EPITT 19976 – New signal

Lead Member State(s): LT

---

<sup>2</sup> Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC

<sup>3</sup> Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

#### 4.1.3. Osimertinib – TAGRISSO (CAP)

---

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Signal of progressive multifocal leukoencephalopathy

**Action:** For adoption of PRAC recommendation

EPITT 19984 – New signal

Lead Member State(s): NL

#### 4.1.4. Tozinameran - COMIRNATY (CAP)

---

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Signal of postmenopausal haemorrhage

**Action:** For adoption of PRAC recommendation

EPITT 19989 – New signal

Lead Member State(s): NL

### 4.2. New signals detected from other sources

None

### 4.3. Signals follow-up and prioritisation

#### 4.3.1. Amivantamab - RYBREVANT (CAP) - EMEA/H/C/005454/SDA/006

---

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Signal of anaphylactic reaction

**Action:** For adoption of PRAC recommendation

EPITT 19928 – Follow up to June 2023

#### 4.3.2. Dapagliflozin – EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/015, FORXIGA (CAP) - EMEA/H/C/002322/SDA/028, EBYMECT (CAP) - EMEA/H/C/004162/SDA/014, XIGDUO (CAP) - EMEA/H/C/002672/SDA/017, QTERN (CAP) - EMEA/H/C/004057/SDA/009

---

Applicant: AstraZeneca AB

PRAC Rapporteur: Mari Thorn

Scope: Signal of acquired phimosis and phimosis with dapagliflozin

**Action:** For adoption of PRAC recommendation

EPITT 19935 – Follow up to June 2023

- 4.3.3. Glucagon-like peptide-1 (GLP-1) receptor agonists: dulaglutide – TRULICITY (CAP) - EMEA/H/C/002825/SDA/014; exenatide – BYDUREON (CAP) - EMEA/H/C/002020/SDA/029, BYETTA (CAP) - EMEA/H/C/000698/SDA/049; insulin degludec, liraglutide – XULTOPHY (CAP) - EMEA/H/C/002647/SDA/005; liraglutide – SAXENDA (CAP) - EMEA/H/C/003780/SDA/019, VICTOZA (CAP) - EMEA/H/C/001026/SDA/039; insulin glargine, lixisenatide – SULIQUA (CAP) - EMEA/H/C/004243/SDA/008; lixisenatide - LYXUMIA (CAP) - EMEA/H/C/002445/SDA/016; semaglutide – OZEMPIC (CAP) - EMEA/H/C/004174/SDA/007, RYBELSUS (CAP) - EMEA/H/C/004953/SDA/012, WEGOVY (CAP) - EMEA/H/C/005422/SDA/006
- 

Applicant: AstraZeneca AB (Bydureon, Byetta), Eli Lilly Nederland B.V. (Trulicity), Novo Nordisk A/S (Ozempic, Rybelsus, Saxenda, Victoza, Wegovy, Xultophy), Sanofi Winthrop Industrie (Lyxumia, Suliqua)

PRAC Rapporteur: Mari Thorn

Scope: Signal of thyroid cancer

**Action:** For adoption of PRAC recommendation

EPITT 18292 – Follow up to April 2023

#### 4.4. Variation procedure(s) resulting from signal evaluation

None

## 5. Risk management plans (RMPs)

### 5.1. Medicines in the pre-authorisation phase

#### 5.1.1. Bevacizumab - EMEA/H/C/005723

---

Scope: Treatment of neovascular (wet) age-related macular degeneration (nAMD)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.2. Catumaxomab - EMEA/H/C/005697

---

Scope: Treatment of malignant ascites

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.3. Cefepime, enmetazobactam - EMEA/H/C/005431

---

Scope: Treatment of: 1) complicated urinary tract infections (including pyelonephritis); 2) hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP); 3) patients with bacteraemia that occurs in association with, or is suspected to be associated

with, any of the infections listed above and 4) infections due to aerobic Gram-negative organisms in adults with limited treatment options

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.4. Danicopan - EMEA/H/C/005517, PRIME, Orphan

---

Applicant: Alexion Europe

Scope: Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.5. Influenza vaccine (H5N1)<sup>4</sup> - EMEA/H/C/006052

---

Scope: Active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.6. Influenza vaccine (H5N1)<sup>5</sup> - EMEA/H/C/006051

---

Scope: Prophylaxis of influenza

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.7. Lecanemab - EMEA/H/C/005966

---

Scope: Disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer's disease and Mild Alzheimer's disease (Early Alzheimer's disease)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.8. Paliperidone - EMEA/H/C/006185

---

Scope: Treatment of schizophrenia

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.1.9. Polihexanide - EMEA/H/C/005858, Orphan

---

Applicant: SIFI SPA

Scope: Treatment of acanthamoeba keratitis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

<sup>4</sup> Virus A/turkey/Turkey/1/2005 (H5N1) NIBERG-23 strain, HA surface antigen

<sup>5</sup> Virus A/turkey/Turkey/1/2005 (H5N1) NIBERG-23 strain, HA surface antigen

#### 5.1.10. Pomalidomide - EMEA/H/C/006195

---

Scope: Treatment of adult patients with relapsed and refractory multiple myeloma (MM) in combination with dexamethasone

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.2. Medicines in the post-authorisation phase – PRAC-led procedures

#### 5.2.1. Dexamethasone - OZURDEX (CAP) - EMEA/H/C/001140/II/0044

---

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of an updated Annex II and RMP version 11 in order to remove additional risk minimisation measure: Patient guide, audio CD (where required)

**Action:** For adoption of PRAC Assessment Report

#### 5.2.2. Emtricitabine, tenofovir disoproxil - EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004137/WS2486/0025

---

Applicant: Zentiva k.s.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of an updated RMP version 5.1 for Emtricitabine/Tenofovir disoproxil in line with the reference medicinal product Truvada (EMEA/H/C/WS2320)

**Action:** For adoption of PRAC Assessment Report

#### 5.2.3. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2515/0018; VIMPAT (CAP) - EMEA/H/C/000863/WS2515/0100

---

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP version 17.0 in order to introduce new updates including the removal of category 3 study EP0158 due to study closure by lack of enrolment, and the removal of category 3 studies (SP848 and EP0034)

**Action:** For adoption of PRAC Assessment Report

#### 5.2.4. Lenvatinib - LENVIMA (CAP) - EMEA/H/C/003727/II/0053

---

Applicant: Eisai GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of section 5.1 of the SmPC in order to update safety and efficacy information for the hepatocellular carcinoma (HCC) indication, based on interim results from study E7080-M000-508 (STELLAR), listed as a category 3 PASS in the RMP. This is a non-interventional multicentre, observational, phase 4 study to evaluate the safety and

tolerability of lenvatinib in patients with advanced or unresectable HCC. RMP version 15.2 has also been submitted

**Action:** For adoption of PRAC Assessment Report

#### 5.2.5. [Tixagevimab, cilgavimab - EVUSHELD \(CAP\) - EMEA/H/C/005788/II/0013](#)

---

Applicant: AstraZeneca AB

PRAC Rapporteur: Kimmo Jaakkola

Scope: Submission of an updated RMP version 5 succession 1 to remove the commitment to conduct the PASS D8850R00006: a post-authorisation observational study of women exposed to EVUSHELD during pregnancy (O-STEREO)

**Action:** For adoption of PRAC Assessment Report

#### 5.2.6. [Tofacitinib - XELJANZ \(CAP\) - EMEA/H/C/004214/II/0054](#)

---

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Submission of an updated RMP version 31.1 in order to modify study A3921427 from an interventional to a non-interventional study. In addition, the MAH has taken the opportunity to update other sections of the RMP

**Action:** For adoption of PRAC Assessment Report

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

#### 5.3.1. [Alglucosidase alfa - MYOZYME \(CAP\) - EMEA/H/C/000636/II/0095](#)

---

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: Update of sections 4.4 and 5.2 of the SmPC in order to update warning on immunogenicity. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.2. [Aripiprazole - ABILIFY MAINTENA \(CAP\) - EMEA/H/C/002755/X/0045](#)

---

Applicant: Otsuka Pharmaceutical Netherlands B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection). The RMP (version 12.1) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP



### 5.3.3. Avapritinib - AYVAKYT (CAP) - EMEA/H/C/005208/II/0023, Orphan

---

Applicant: Blueprint Medicines (Netherlands) B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomised, double-blind, placebo-controlled, phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.4. Azacitidine - AZACITIDINE ACCORD (CAP) - EMEA/H/C/005147/X/0013

---

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Menno van der Elst

Scope: Extension application to introduce a new pharmaceutical form associated with a new strength (10 mg/ml powder for solution for infusion) and a new route of administration (intravenous use). The RMP version 2 is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.5. Bempedoic acid - NILEMDO (CAP) - EMEA/H/C/004958/II/0031

---

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk, based on results from study 1002-043 (CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen]). CLEAR outcomes study is a phase 3 multi-centre randomised, double-blind, placebo-controlled study to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly. Version 4.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor formatting changes to the product information. As part of the application, the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.6. Bempedoic acid, ezetimibe - NUSTENDI (CAP) - EMEA/H/C/004959/II/0035

---

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk for NUSTENDI, based on results from Study 1002-043, known as the CLEAR [Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL) Inhibiting Regimen] outcomes trial, a phase 3, randomised, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. [Budesonide, formoterol fumarate dihydrate - BUDESONIDE/FORMOTEROL TEVA PHARMA B.V. \(CAP\) - EMEA/H/C/004882/II/0012/G](#)

---

Applicant: Teva Pharma B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Grouped variations consisting of: 1) To replace the multidose dry powder inhaler to be used for the delivery of a combination of Budesonide/Formoterol fumarate dihydrate inhalation powder, as well as detect, record, store and transfer inhaler usage information to a mobile application (App); the inhaler is an integrated part of the primary packaging of the medicinal product; 2) To change the name of the medicinal product 3) To update sections 4.2 and 4.4 of the SmPC to reorganise the flow of information within these sections (as approved for DuoResp Spiromax EMEA/H/C/002348), following assessment of the same change for the reference product Symbicort Turbohaler; 4) other quality variations

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8. [Cariprazine - REAGILA \(CAP\) - EMEA/H/C/002770/II/0034](#)

---

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Update of sections 4.3 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The package leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.9. [Cariprazine - REAGILA \(CAP\) - EMEA/H/C/002770/X/0033](#)

---

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Extension application to introduce a new pharmaceutical form (orodispersible tablets). The RMP (version 3.0) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.10. [Concentrate of proteolytic enzymes enriched in bromelain - NEXOBRID \(CAP\) - EMEA/H/C/002246/II/0058](#)

---

Applicant: MediWound Germany GmbH

PRAC Rapporteur: Martin Huber

Scope: Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as Study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2-arm study aiming to demonstrate the superiority of NexoBrid treatment over standard of care (SOC) treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated accordingly. Version 9 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.11. [Dabigatran etexilate - PRADAXA \(CAP\) - EMEA/H/C/000829/II/0147/G](#)

---

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: A grouped application consisting of:

C.I.7.a (type IB): 1) to delete the pharmaceutical form "powder and solvent for oral solution, 6.25 mg/ml", as agreed in procedure EMEA/H/C/000829/II/0144.

C.I.4 (type II): 2) Update of section 4.1 of the SmPC in order to modify the indication following the deletion of the powder and solvent for oral solution; the package leaflet is updated accordingly. The RMP version 41.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information and update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.12. [Denosumab - PROLIA \(CAP\) - EMEA/H/C/001120/II/0099](#)

---

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to update a warning regarding hypocalcaemia and to include reports of life-threatening events and fatal cases occurred in the post marketing setting, particularly in patients with severe renal impairment, receiving dialysis or treatment with other calcium lowering drugs based on the cumulative review of

MAH safety database and literature. The package leaflet is updated accordingly. The RMP version 32.0 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.13. Faricimab - VABYSMO (CAP) - EMEA/H/C/005642/II/0005

---

Applicant: Roche Registration GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Extension of indication to include treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) for Vabysmo, based on results from the two phase 3 studies: GR41984 (BALATON) in patients with branch retinal vein occlusion (BRVO) and GR41986 (COMINO) in patients with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). These are global, multicentre, randomised, double-masked, active comparator-controlled, parallel-group, 2-part studies evaluating the efficacy, safety, and PK of faricimab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The package leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.14. Hydroxycarbamide - XROMI (CAP) - EMEA/H/C/004837/II/0019

---

Applicant: Nova Laboratories Ireland Limited

PRAC Rapporteur: Jo Robays

Scope: Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 6 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-centre study in children with sickle cell anaemia over 6 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.15. Idecabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0031, Orphan

---

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP<sup>6</sup>

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety

---

<sup>6</sup> Advanced therapy medicinal product

of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the product information is brought in line with the Guideline on core SmPC, labelling and package leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

### 5.3.16. [Infliximab - REMSIMA \(CAP\) - EMEA/H/C/002576/II/0133/G](#)

---

Applicant: Celltrion Healthcare Hungary Kft.

PRAC Rapporteur: Kimmo Jaakkola

Scope: Grouped application comprising three type II variations (C.I.4) as follows:

- 1) Update of section 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on Week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn's disease), listed as a category 3 study in the RMP; Study CT-P13 3.7 is a randomised, placebo controlled, double-blind, phase 3 study to evaluate the efficacy and safety of the subcutaneous injection of CT-P13 (CT-P13 SC) as maintenance therapy in patients with moderately to severely active ulcerative colitis and study CT-P13 3.8 is a randomised, placebo-controlled, double-blind, phase 3 study to evaluate the efficacy and safety of the subcutaneous injection of CT-P13 (CT-P13 SC) as maintenance therapy in patients with moderately to severely active Crohn's disease.
- 2) Update of section 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- 3) Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg every two weeks based on data from REMSWITCH study (Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH Study). The RMP version 16.1 has also been submitted. The package leaflet and labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.17. [Influenza vaccine \(surface antigen, inactivated, adjuvanted\) - FLUAD TETRA \(CAP\) - EMEA/H/C/004993/II/0043](#)

---

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Extension of indication to include adults 50 years of age and older for Flud Tetra, based on final results from study V118\_23; this is a phase 3, randomised, observer-blind, controlled, multicentre, clinical study to evaluate immunogenicity and safety of an MF59-adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections

4.1, 4.8 and 5.1 of the SmPC are updated. The labelling and package leaflet are updated in accordance. Version 2.9 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.18. Mecasermin - INCRELEX (CAP) - EMEA/H/C/000704/II/0080

Applicant: Ipsen Pharma

PRAC Rapporteur: Kirsti Villikka

Scope: Update of sections 4.2, 4.6, and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of pre-prandial blood glucose in pre prandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGD deficiency (IGFD) based on the cumulative review of safety database, scientific literature and clinical trials data. The package leaflet is updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.19. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0039

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update of sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC in order to update information regarding the use of naloxegol in opioid-induced constipation (OIC) patients with cancer-related pain based on real-world data from non-interventional studies (NACASY, KYONAL, and MOVE studies), post-marketing data, and literature. The package leaflet is updated accordingly. The RMP version 8 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.20. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0136

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post marketing and clinical study data. The package leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.21. [Opicapone - ONGENTYS \(CAP\) - EMEA/H/C/002790/WS2552/0060; ONTILYV \(CAP\) - EMEA/H/C/005782/WS2552/0015](#)

---

Applicant: Bial Portela & Companhia S.A.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Extension of indication to include treatment of signs and symptoms of Parkinson's Disease for Ongentys/Ontilyv, based on final results from study BIA-91067-303; this is a pivotal Phase III, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of opicapone in patients with early idiopathic Parkinson's Disease receiving treatment with L-DOPA plus a DDCI, and who are without signs of any motor complication. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted (only applicable to Ongentys) to reflect the changes made upon approval of the informed consent application, to keep consistency between the eCTD lifecycles of the two marketing authorisations (Ongentys and Ontilyv). Furthermore, the product information is brought in line with the latest QRD template version 10.3. In addition, as part of the application the MAH is requesting a 1-year extension of the market protection

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.22. [Patiromer - VELTASSA \(CAP\) - EMEA/H/C/004180/X/0031/G](#)

---

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Kirsti Villikka

Scope: Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 6 to 18 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.23. [Pegcetacoplan - ASPAVELI \(CAP\) - EMEA/H/C/005553/II/0011, Orphan](#)

---

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Kimmo Jaakkola

Scope: Extension of indication to include treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a phase III, randomised, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.24. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0138

---

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include Keytruda in combination with gemcitabine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a phase 3 randomised, double-blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 43.1 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.25. Pralsetinib - GAVRETO (CAP) - EMEA/H/C/005413/II/0012

---

Applicant: Roche Registration GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of sections 4.2, 4.4 and 4.5 of the SmPC in order to amend posology recommendations, warnings and drug-drug interaction (DDI) information regarding the co-administration with CYP3A4 inhibitors, P-gp inhibitors and CYP3A4 inducers based on final results from the DDI study GP43162, listed as a category 3 study in the RMP, as well as results from the physiologically based pharmacokinetic (PBPK) analyses summarised in the PBPK Report 1120689. Study GP43162 is a phase 1, open-label, fixed-sequence study to evaluate the effect of a single dose of cyclosporine on the single dose pharmacokinetics of pralsetinib in healthy subjects. The RMP version 1.6 has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.26. Saxagliptin - ONGLYZA (CAP) - EMEA/H/C/001039/II/0057

---

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information in paediatric patients with Type 2 diabetes mellitus (T2DM) aged 10 to <18 years of age based on interim results from study D1680C00019 (T2NOW). This is a 26-week, multicentre, randomised, placebo-controlled, double-blind, parallel group, Phase III trial with a 26-week safety extension period evaluating the safety and efficacy of dapagliflozin (5 and 10 mg), and, separately, saxagliptin (2.5 and 5 mg) in paediatric patients with T2DM who were between 10 and below 18 years of age. The package leaflet is updated accordingly. The RMP version 17.1 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template and to introduce editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP



### 5.3.27. [Selixipag - UPTRAVI \(CAP\) - EMEA/H/C/003774/X/0038](#)

---

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Nathalie Gault

Scope: Extension application to add a new strength of 100 µg film-coated tablets in HDPE bottle. The RMP (version 10.1) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.28. [Selpercatinib - RETSEVMO \(CAP\) - EMEA/H/C/005375/II/0021](#)

---

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET) fusion-positive thyroid cancer in the first-line setting for RETSEVMO based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumors. LIBRETTO-121 is a phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.29. [Selpercatinib - RETSEVMO \(CAP\) - EMEA/H/C/005375/II/0022](#)

---

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include the treatment of adults with advanced or metastatic rearranged during transfection (RET) fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.30. [Sotorasib - LUMYKRAS \(CAP\) - EMEA/H/C/005522/II/0007](#)

---

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study

20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version 10.3

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.31. [Spesolimab - SPEVIGO \(CAP\) - EMEA/H/C/005874/X/0006/G](#)

---

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Nathalie Gault

Scope: Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration (subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. This line extension is grouped with a type II variation (C.I.6.a) to extend indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-centre, randomised, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and package leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the product information and update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.32. [Tisagenlecleucel - KYMRIA \(CAP\) - EMEA/H/C/004090/II/0075, Orphan](#)

---

Applicant: Novartis Europharm Limited, ATMP<sup>7</sup>

PRAC Rapporteur: Gabriele Maurer

Scope: Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTL019C2201 PAES in the Annex II (ANX008); this is a Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The RMP version 6 has also been submitted. In addition, the MAH took the opportunity to update Annex II.D of the product information

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

---

<sup>7</sup> Advanced therapy medicinal product

### 5.3.33. [Tozinameran - COMIRNATY \(CAP\) - EMEA/H/C/005735/II/0188/G](#)

---

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Grouped application comprising two type II variations as follows:

C.I.4 – 1) Update of section 4.8 of the SmPC in order to update the safety information based on interim (6MPD3 in 12-15yo) and final results from study C4591001, listed as a category 3 study in the RMP. This is a phase 1/2/3, placebo-controlled, randomised, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. An updated RMP version 10.1 has also been submitted.

C.I.11.b – 2) Submission of an updated RMP version 10.1 in order to revise RMP milestones of final study reports of other on-going procedures, including other administrative and editorial changes

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

## 6. Periodic safety update reports (PSURs)

### 6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

#### 6.1.1. [Avacopan - TAVNEOS \(CAP\) - PSUSA/00010967/202303](#)

---

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.2. [Avelumab - BAVENCIO \(CAP\) - PSUSA/00010635/202303](#)

---

Applicant: Merck Europe B.V.

PRAC Rapporteur: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.3. [Betaine anhydrous<sup>8</sup> - CYSTADANE \(CAP\) - PSUSA/00000390/202302](#)

---

Applicant: Recordati Rare Diseases

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

---

<sup>8</sup> Centrally authorised product(s) only

**Action:** For adoption of recommendation to CHMP

#### 6.1.4. Bupivacaine, meloxicam - ZYNRELEF<sup>9</sup> - PSUSA/00010880/202303

Applicant: Heron Therapeutics, B.V.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For discussion

#### 6.1.5. Cabotegravir - VOCABRIA (CAP) - PSUSA/00010900/202303

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.6. Cenobamate - ONTOZRY (CAP) - PSUSA/00010921/202303

Applicant: Angelini S.p.A.

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.7. Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202303

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.8. Ciclosporin<sup>10</sup> - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202303

Applicant: Santen Oy

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

<sup>9</sup> European Commission (EC) decision on the marketing authorisation (MA) withdrawal of Zynrelef dated 05 October 2023

<sup>10</sup> For topical use only

#### 6.1.9. Dabigatran - PRADAXA (CAP) - PSUSA/00000918/202303

---

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.10. Dimethyl fumarate<sup>11</sup> - SKILARENCE (CAP) - PSUSA/00010647/202303

---

Applicant: Almirall S.A

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.11. Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202303

---

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.12. Duvelisib - COPIKTRA (CAP) - PSUSA/00010939/202303

---

Applicant: Secura Bio Limited

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.13. Eftrenonacog alfa - ALPROLIX (CAP) - PSUSA/00010499/202303

---

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.14. Filgotinib - JYSELECA (CAP) - PSUSA/00010879/202303

---

Applicant: Galapagos N.V.

PRAC Rapporteur: Nikica Mirošević Skvrce

---

<sup>11</sup> Psoriasis

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.15. Fingolimod - GILENYA (CAP) - PSUSA/00001393/202302

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.16. Gozetotide - LOCAMETZ (CAP) - PSUSA/00011030/202303

Applicant: Novartis Europharm Limited

PRAC Rapporteur: John Joseph Borg

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.17. Ibritumomab tiuxetan - ZEVALIN (CAP) - PSUSA/00001704/202302

Applicant: Ceft Biopharma s.r.o.

PRAC Rapporteur: Karin Ernehalm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.18. Idecabtagene vicleucel - ABECMA (CAP) - PSUSA/00010954/202303

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP<sup>12</sup>

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

#### 6.1.19. Lasmiditan - RAYVOW (CAP) - PSUSA/00011011/202304

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Anna Mareková

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

<sup>12</sup> Advanced therapy medicinal product

#### 6.1.20. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202303

---

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.21. Lutetium (<sup>177</sup>Lu) vipivotide tetraxetan - PLUVICTO (CAP) - PSUSA/00011031/202303

---

Applicant: Novartis Europharm Limited

PRAC Rapporteur: John Joseph Borg

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.22. Maralixibat - LIVMARLI (CAP) - PSUSA/00011032/202303

---

Applicant: Mirum Pharmaceuticals International B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.23. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202303

---

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.24. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202303

---

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.25. Niraparib - ZEJULA (CAP) - PSUSA/00010655/202303

---

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.26. Nivolumab, relatlimab - OPDUALAG (CAP) - PSUSA/00011018/202303

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.27. Ofatumumab - KESIMPTA (CAP) - PSUSA/00010927/202303

Applicant: Novartis Ireland Limited

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.28. Olipudase alfa - XENPOZYME (CAP) - PSUSA/00011003/202303

Applicant: Sanofi B.V.

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.29. Oritavancin - TENKASI (CAP) - PSUSA/00010368/202303

Applicant: Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.30. Ponesimod - PONVORY (CAP) - PSUSA/00010940/202303

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.31. Rilpivirine<sup>13</sup> - REKAMBYS (CAP) - PSUSA/00010901/202303

Applicant: Janssen-Cilag International N.V.

---

<sup>13</sup> For intramuscular use only



PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.32. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202303

Applicant: AbbVie Deutschland GmbH & Co. KG  
PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.33. Selinexor - NEXPOVIO (CAP) - PSUSA/00010926/202303

Applicant: Stemline Therapeutics B.V.  
PRAC Rapporteur: Menno van der Elst  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.34. Selumetinib - KOSELUGO (CAP) - PSUSA/00010936/202304

Applicant: AstraZeneca AB  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.35. Siponimod - MAYZENT (CAP) - PSUSA/00010818/202303

Applicant: Novartis Europharm Limited  
PRAC Rapporteur: Maria del Pilar Rayon  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.36. Solriamfetol - SUNOSI (CAP) - PSUSA/00010831/202303

Applicant: Atnahs Pharma Netherlands B.V.  
PRAC Rapporteur: Julia Pallos  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

#### 6.1.37. Tebentafusp - KIMMTRAK (CAP) - PSUSA/00010991/202303

---

Applicant: Immunocore Ireland Limited

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.38. Tepotinib - TEPMETKO (CAP) - PSUSA/00010979/202303

---

Applicant: Merck Europe B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.39. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202303

---

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.40. Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202303

---

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.1.41. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202303

---

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

## 6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

### 6.2.1. Pramipexole - MIRAPEXIN (CAP); SIFROL (CAP); NAP - PSUSA/00002491/202304

---

Applicant: Boehringer Ingelheim International GmbH (Mirapexin, Sifrol), various

PRAC Rapporteur: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.2.2. Timolol, travoprost - DUOTRAV (CAP); NAP - PSUSA/00002962/202302

---

Applicant: Novartis Europharm Limited (DuoTrav), various

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

## 6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

### 6.3.1. BCG (bacillus calmette-guérin) for Immunotherapy (NAP) - PSUSA/00000303/202303

---

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.2. BCG vaccine (freeze-dried) (NAP) - PSUSA/00000304/202303

---

Applicant(s): various

PRAC Lead: Roxana Dondera

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.3. Bicalutamide (NAP) - PSUSA/00000407/202302

---

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.4. Dienogest, ethinylestradiol (NAP) - PSUSA/00001057/202303

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.5. Ethosuximide (NAP) - PSUSA/00001316/202303

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.6. Fluconazole (NAP) - PSUSA/00001404/202303

Applicant(s): various

PRAC Lead: Marie Louise Schougaard Christiansen

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.7. Furosemide, spironolactone (NAP) - PSUSA/00001493/202303

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.8. Human plasma<sup>14</sup> (NAP) - PSUSA/00001635/202302

Applicant(s): various

PRAC Lead: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.9. Oxycodone (NAP) - PSUSA/00002254/202304

Applicant(s): various

---

<sup>14</sup> Pooled and treated for virus inactivation

PRAC Lead: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

## 6.4. Follow-up to PSUR/PSUSA procedures

### 6.4.1. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/LEG 017.2

---

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Eva Jirsová

Scope: From II-0031: Commitment to provide targeted tumour lysis syndrome (TLS) assessment reports on a biannual basis (submitted annually within the PSUR, and 6 months after the PSUR submission in a separate report) through 2023, and annually thereafter, as per the RMP v8.0. These biannual assessment reports ensure close monitoring of the important identified risk of TLS, and the evaluation of the impact of newly implemented risk minimisation measures for TLS, on adherence to both already existing and updated recommendation added to the SmPC, the impact of the DHPC distributed to haematologists, and the patient card

**Action:** For adoption of advice to CHMP

## 6.5. Variation procedure(s) resulting from PSUSA evaluation

### 6.5.1. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0243

---

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Mari Thorn

Scope: To update section 4.8 of the SmPC to add weight increased to the list of adverse drug reactions (ADRs) with frequency uncommon following PRAC PSUR assessment report (EMA/PRAC/158162/2023-Corr.1) based on the cumulative literature review. The package leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes

**Action:** For adoption of PRAC Assessment Report

### 6.5.2. Laronidase - ALDURAZYME (CAP) - EMEA/H/C/000477/II/0085

---

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: To update section 4.2 of the SmPC in order to modify the administration instructions following the periodic safety update single assessment (PSUSA) procedure (PSUSA/00001830/202104) adopted in December 2021<sup>15</sup> based on literature review. The package leaflet is updated accordingly. The RMP version 1.0 has also been submitted

---

<sup>15</sup> Held 29 November – 02 December 2021

**Action:** For adoption of PRAC Assessment Report

## 6.6. Expedited summary safety reviews<sup>16</sup>

None

## 7. Post-authorisation safety studies (PASS)

### 7.1. Protocols of PASS imposed in the marketing authorisation(s)<sup>17</sup>

#### 7.1.1. Alemtuzumab - Lemtrada (CAP) - EMEA/H/C/PSA/S/0107

---

Applicant: Blueprint Medicines (Netherlands) B.V.

PRAC Rapporteur: Karin Erneholm

Scope: Substantial amendment to the protocol of a non-interventional PASS to investigate drug utilisation and safety monitoring patterns for Lemtrada (alemtuzumab)

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

#### 7.1.2. Valproate<sup>18</sup> (NAP) - EMEA/H/N/PSP/J/0075.13

---

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Responses to the 2<sup>nd</sup> RSI of the 4<sup>th</sup> interim report and statistical analysis plan for drug utilisation study (DUS) extension (DUS ext.) to assess the effectiveness of the new risk minimisation measures and to further characterise the prescribing patterns for valproate and related substances [MAH's response to PSP/J/0075.12]

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)<sup>19</sup>

#### 7.2.1. Avatrombopag - DOPTLET (CAP) - EMEA/H/C/004722/MEA 003.4

---

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Monica Martinez Redondo

Scope: MAH's response to MEA 003.3 and revised protocol for a study to further characterise the long-term safety profile of avatrombopag in patients with primary chronic

---

<sup>16</sup> Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

<sup>17</sup> In accordance with Article 107n of Directive 2001/83/EC

<sup>18</sup> Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

<sup>19</sup> In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

immune thrombocytopenia in European patient registers and electronic healthcare databases as requested in the conclusions of variation II/0004/G finalised in December 2020 as per the request for supplementary information (RSI) adopted June 2023

**Action:** For adoption of advice to CHMP

#### 7.2.2. [Cannabidiol - EPIDYOLEX \(CAP\) - EMEA/H/C/004675/MEA 007.3](#)

---

Applicant: Jazz Pharmaceuticals Ireland Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: MAH's response to MEA 007.2 [protocol amendment for study GWEP19022 (listed as a category 3 study in the RMP): a prospective, observational cohort long-term safety study to assess the potential for chronic liver injury in patients treated with Epidyolex (cannabidiol oral solution) when used under conditions of routine clinical care] as per the request for supplementary information (RSI) adopted in July 2021

**Action:** For adoption of advice to CHMP

#### 7.2.3. [Coronavirus \(COVID-19\) vaccine \(recombinant protein receptor binding domain fusion heterodimer\) - BIMERVAX \(CAP\) - EMEA/H/C/006058/MEA 008](#)

---

Applicant: Hipra Human Health S.L.

PRAC Rapporteur: Zane Neikena

Scope: Protocol submission for the non-imposed, non-interventional, category 3 post authorisation observational study to assess the safety of Bimervax using electronic health record (HER) databases in Europe (PASS VAC4EU)

**Action:** For adoption of advice to CHMP

#### 7.2.4. [Coronavirus \(COVID-19\) vaccine \(recombinant protein receptor binding domain fusion heterodimer\) - BIMERVAX \(CAP\) - EMEA/H/C/006058/MEA 009](#)

---

Applicant: Hipra Human Health S.L.

PRAC Rapporteur: Zane Neikena

Scope: Protocol submission for the non-imposed, non-interventional, category 3 PASS of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) to assess the occurrence of obstetric, neonatal, and infant outcomes among women administered with Bimervax during pregnancy

**Action:** For adoption of advice to CHMP

#### 7.2.5. [Ivosidenib - TIBSOVO \(CAP\) - EMEA/H/C/005936/MEA 003](#)

---

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Protocol submission for a non-imposed/non-interventional, category 3 study in the RMP to evaluate the effectiveness of the Ivosidenib Patient Alert Card included in the

additional risk minimisation measures, for awareness of differentiation syndrome in acute myeloid leukaemia (AML) patients, using process indicators for awareness, receipt of the material, utility and knowledge

**Action:** For adoption of advice to CHMP

#### 7.2.6. Linaclotide - CONSTELLA (CAP) - EMEA/H/C/002490/MEA 009.7

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Martin Huber

Scope: Amendment to a protocol previously agreed for PASS EVM-18888: linaclotide safety study assessing the complications of diarrhoea and associated risk factors in selected European populations with irritable bowel syndrome with constipation (IBS-C) for Constella (linaclotide) 290µg capsule (protocol version 13)

**Action:** For adoption of advice to CHMP

#### 7.2.7. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 001

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Submission of protocol for a non-imposed, non-interventional post-authorisation long-term observational study in Europe (MAVEL-HCM) in a real-world setting in patients with obstructive hypertrophic cardiomyopathy (oHCM) to characterise the following safety concerns: 'heart failure due to systolic dysfunction', 'patients with Class IV NYHA', 'patients being treated with disopyramide', 'patients being treated with a combination of β-blockers and non-dihydropyridine calcium-channel blockers (verapamil/diltiazem)', and 'long-term safety, including detrimental CV effects'

**Action:** For adoption of advice to CHMP

#### 7.2.8. Mavacamten - CAMZYOS (CAP) - EMEA/H/C/005457/MEA 002

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: Submission of a protocol for a non-imposed, non-interventional (CV027-1148) meta-analysis of phase 3, placebo-controlled, double-blind, randomised studies of mavacamten in patients with symptomatic hypertrophic cardiomyopathy (HCM), to evaluate the cardiovascular safety profile based on a composite endpoint of time to first occurrence of major cardiovascular event (MACE) meta-analysis event, including three clinical trials in symptomatic obstructive hypertrophic cardiomyopathy (HCM) population (EXPLORER-HCM, VALOR-HCM, China oHCM Phase 3 trial) and one clinical trial in symptomatic non-obstructive HCM population (ODYSSEY-HCM)

**Action:** For adoption of advice to CHMP



### 7.2.9. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.7

---

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: MAH's response to MEA 001.6 [protocol amendment for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance ] as per the request for supplementary information adopted in July 2023

**Action:** For adoption of advice to CHMP

### 7.2.10. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.7

---

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: MAH's response to MEA 002.6 [protocol amendment for study OP0004: European non-interventional PASS to evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance] as per the request for supplementary information adopted in July 2023

**Action:** For adoption of advice to CHMP

### 7.2.11. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.5

---

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: MAH's response to MEA 003.4 [protocol amendment for study OP0006: evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance] as per the request for supplementary information adopted in July 2023

**Action:** For adoption of advice to CHMP

### 7.2.12. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 002.1

---

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 002 [protocol for study I8F-MC-B011: Tirzepatide Pancreatic Malignancy Study to evaluate the incidence of pancreatic malignancy among patients with type 2 diabetes mellitus (T2DM) treated with tirzepatide and to compare the incidence of pancreatic malignancy among patients treated with tirzepatide to patients treated with alternative treatments for clinical indications approved for GLP-1 Ras in Europe] as per the request for supplementary information adopted in April 2023

**Action:** For adoption of advice to CHMP

#### 7.2.13. Tirzepatide - MOUNJARO (CAP) - EMEA/H/C/005620/MEA 005.1

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 005 [protocol for study I8F-MC-B013: a database linkage study to evaluate the important potential risk of medullary thyroid cancer] as per the request for supplementary information adopted in April 2023

**Action:** For adoption of advice to CHMP

#### 7.2.14. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 037.5

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 037.4 [A non-interventional PASS in US to assess the occurrence of safety events of interest, including myocarditis and pericarditis, among individuals in the general US population and in subcohorts of interest within selected data sources participating in the US Sentinel System] as per request for supplementary information (RSI) adopted in February 2023

**Action:** For adoption of advice to CHMP

#### 7.2.15. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 017.1

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Revised protocol for study P23-480: a comparative cohort study of long-term safety of upadacitinib for the treatment of ulcerative colitis and Chron's disease in a real-world setting in Europe

**Action:** For adoption of advice to CHMP

#### 7.2.16. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 044.17

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's response to MEA 044.16 [PASS CNTO1275PSO4056] as per request for supplementary information (RSI) adopted in June 2023:

Progress report / Request for supplementary information required by 7 August 2023:

The MAH is asked to provide further information on the following events, considered by the investigator related to ustekinumab: Tinea versicolour, Balanitis candida

**Action:** For adoption of advice to CHMP

### 7.2.17. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - EMEA/H/C/005830/MEA 005.1

---

Applicant: BioMarin International Limited, ATMP<sup>20</sup>

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 005 [Protocol of a survey of Haematologists to Assess the Effectiveness of the Additional Risk Minimisation Measures for ROCTAVIAN addressing the outstanding points in the MEA005 assessment report] as per request for supplementary information (RSI) adopted in June 2023

**Action:** For adoption of advice to CAT and CHMP

### 7.2.18. Voclosporin - LUPKYNIS (CAP) - EMEA/H/C/005256/MEA 002.1

---

Applicant: Otsuka Pharmaceutical Netherlands B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to MEA 002 [protocol No 348-201-00021: non-imposed/non-interventional, listed as category 3 study in the RMP, observational PASS in Europe to further characterise and quantify long-term safety profile with respect to neurotoxicity, chronic nephrotoxicity, and malignancy with use of voclosporin] as per the request for supplementary information (RSI) adopted in June 2023

**Action:** For adoption of advice to CHMP

## 7.3. Results of PASS imposed in the marketing authorisation(s)<sup>21</sup>

### 7.3.1. Valproate<sup>22</sup> (NAP) - EMEA/H/N/PSR/J/0043

---

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Final study report for a retrospective observational study to investigate the association between paternal exposure to valproate and the risk of congenital anomalies and neurodevelopmental disorders including autism in offspring

**Action:** List of experts and list of questions (LoQ) for stakeholder's meeting/SAG

### 7.3.2. Valproate<sup>23</sup> (NAP) - EMEA/H/N/PSR/J/0045

---

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Jean-Michel Dogné

Scope: Final study report for a non-interventional retrospective longitudinal study in the United Kingdom and France to investigate the therapeutic strategies after discontinuation of valproate and related substances in clinical practice

---

<sup>20</sup> Advanced therapy medicinal product

<sup>21</sup> In accordance with Article 107p-q of Directive 2001/83/EC

<sup>22</sup> Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

<sup>23</sup> Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

## 7.4. Results of PASS non-imposed in the marketing authorisation(s)<sup>24</sup>

### 7.4.1. Alglucosidase alfa - MYOZYME (CAP) - EMEA/H/C/000636/II/0093

---

Applicant: Sanofi B.V.

PRAC Rapporteur: Nathalie Gault

Scope: Submission of the final non-interventional Pompe Registry Report 2022 (MEA024 and MEA025)

**Action:** For adoption of PRAC Assessment Report

### 7.4.2. Belimumab - BENLYSTA (CAP) - EMEA/H/C/002015/II/0116

---

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report for the belimumab pregnancy registry (BPR) (BEL114256) listed as a category 3 study in the RMP. This is a non-interventional study to evaluate pregnancy and infant outcomes for pregnancies in women with systemic lupus erythematosus (SLE) exposed to commercially supplied belimumab within the 4 months preconception and/or during pregnancy. In addition, the BPR protocol planned to collect pregnancy and infant outcomes for pregnancies in women with SLE and Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus (SABLE) protocol who were not exposed to belimumab and enrolled in BPR. The RMP version 45.0 has also been submitted

**Action:** For adoption of PRAC Assessment Report

### 7.4.3. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0082

---

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy based on results from study 109MS402 - Tecfidera (dimethyl fumarate) Pregnancy Exposure Registry, listed as a category 3 study in the RMP; this is an observational study and aims to address the safety concern of effects on pregnancy outcome and prospectively evaluates pregnancy outcomes in women with multiple sclerosis (MS) who were exposed to a Registry-specified Biogen MS product during the eligibility window for that product. The package leaflet is updated accordingly. The RMP version 15.1 has also been submitted. In addition, the MAH has taken the opportunity to introduce editorial changes to the product information

**Action:** For adoption of PRAC Assessment Report

---

<sup>24</sup> In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

#### 7.4.4. [Elasomeran - SPIKEVAX \(CAP\) - EMEA/H/C/005791/II/0110](#)

---

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Submission of the final report from study P903 - US PASS (NCT04958954), listed as a category 3 study in the RMP: post-marketing safety of SARS-CoV-2 Spikevax vaccine in the US for the active surveillance, signal refinement and self-controlled risk interval (SCRI) signal evaluation in HealthVerity. This submission addresses the post-authorisation measure MEA/003

**Action:** For adoption of PRAC Assessment Report

#### 7.4.5. [Tacrolimus - ADVAGRAF \(CAP\) - EMEA/H/C/000712/WS2519/0071/G; MODIGRAF \(CAP\) - EMEA/H/C/000954/WS2519/0046/G](#)

---

Applicant: Astellas Pharma Europe B.V.

PRAC Rapporteur: Eamon O Murchu

Scope: A grouped application consisting of: 1) submission of the final report from study F506-PV-0001 listed as a category 3 study in the RMP for Advagraf and Modigraf: NI-PASS of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI). The RMP version 5.0 has also been submitted; and 2) to include the feasibility assessment of using alternative secondary-use data sources to replicate the TPRI study as a category 3 additional pharmacovigilance activity in the RMP, including the milestones for the progress report and the final report of the feasibility assessment, related to EMEA/H/C/000712/MEA/032 and EMEA/H/C/000954/MEA/024

**Action:** For adoption of PRAC Assessment Report

### 7.5. **Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation**

#### 7.5.1. [Avapritinib - AYVAKYT \(CAP\) - EMEA/H/C/005208/SOB 009.1](#)

---

Applicant: Blueprint Medicines (Netherlands) B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Study BLU-285-1406 is an imposed non-interventional PASS aiming to confirm the safety and efficacy of avapritinib in the treatment of adult patients with unresectable or metastatic GIST harbouring the PDGFRA D842V mutation, given as Specific Obligation 3 (SOB3) of the Conditional Marketing Authorisation for AYVAKYT. The submission of the first progress report is in line with agreed milestones in the Final PASS Protocol Assessment Report from the Pharmacovigilance Risk Assessment Committee (procedure number EMEA/H/C/PSP/S/0089.1 issued on 10 June 2021)

**Action:** For adoption of advice to CHMP

### 7.5.2. Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/ANX 002.6

---

Applicant: Kite Pharma EU B.V., ATMP<sup>25</sup>

PRAC Rapporteur: Karin Erneholm

Scope: Title: Long-term, non-interventional study of recipients of Yescarta for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma

**Action:** For adoption of advice to CAT and CHMP

### 7.5.3. Bimekizumab - BIMZELX (CAP) - EMEA/H/C/005316/MEA 005

---

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: From Initial MAA: Study PS0014: A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult study participants with moderate-to-severe chronic plaque PSO. Assess the safety and efficacy of long-term use of bimekizumab

**Action:** For adoption of advice to CHMP

### 7.5.4. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.9

---

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: From Initial MAA: C-VIPER Study (D8110C00003); COVID-19 Vaccines International Pregnancy Registry of Women Exposed to AZD1222 Immediately Before or During Pregnancy

**Action:** For adoption of advice to CHMP

### 7.5.5. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 002

---

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Mari Thorn

Scope: A Multicenter, Randomised, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus and Not on Dialysis With an up to 52-Week Long-term Extension

**Action:** For adoption of advice to CHMP

### 7.5.6. Difelikefalin - KAPRUVIA (CAP) - EMEA/H/C/005612/MEA 003

---

Applicant: Vifor Fresenius Medical Care Renal Pharma France

---

<sup>25</sup> Advanced therapy medicinal product

PRAC Rapporteur: Mari Thorn

Scope: A Multicenter, Randomised, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects With Moderate-to-Severe Pruritus and Not on Dialysis With an up to 52-Week Long-term Extension

**Action:** For adoption of advice to CHMP

#### 7.5.7. [Difelikefalin - KAPRUVIA \(CAP\) - EMEA/H/C/005612/MEA 004](#)

---

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Mari Thorn

Scope: A Two-part, Multicenter, Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects With Atopic Dermatitis

**Action:** For adoption of advice to CHMP

#### 7.5.8. [Givosiran - GIVLAARI \(CAP\) - EMEA/H/C/004775/MEA 006.6](#)

---

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: From Initial MAA: Company Sponsored AHP Registry; A global observational longitudinal prospective registry of patients with acute hepatic porphyria (AHP)

**Action:** For adoption of advice to CHMP

#### 7.5.9. [Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA \(CAP\) - EMEA/H/C/003687/MEA 003.15](#)

---

Applicant: Orexigen Therapeutics Ireland Limited

PRAC Rapporteur: Martin Huber

Scope: PASS Study NB-451: An observational retrospective drug utilisation study (DUS) of Mysimba (naltrexone hydrochloride/bupropion hydrochloride) in Europe and the United States to describe the demographic and baseline characteristics of users of Mysimba, evaluate patterns of Mysimba initiation and use

**Action:** For adoption of advice to CHMP

### 7.6. **Others**

None

### 7.7. **New Scientific Advice**

None

## 7.8. Ongoing Scientific Advice

None

## 7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

# 8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

## 8.1. Annual reassessments of the marketing authorisation

### 8.1.1. Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0062 (without RMP)

---

Applicant: Sandoz Pharmaceuticals d.d.

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.1.2. Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0036 (without RMP)

---

Applicant: Ultragenyx Germany GmbH

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

## 8.2. Conditional renewals of the marketing authorisation

None

## 8.3. Renewals of the marketing authorisation

### 8.3.1. Luspirtrombopag - MULPLEO (CAP) - EMEA/H/C/004720/R/0018 (without RMP)

---

Applicant: Shionogi B.V.

PRAC Rapporteur: Mari Thorn

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP



### 8.3.2. Paclitaxel - PAZENIR (CAP) - EMEA/H/C/004441/R/0015 (with RMP)

---

Applicant: ratiopharm GmbH

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.3.3. Pegvaliase - PALYNZIQ (CAP) - EMEA/H/C/004744/R/0038 (without RMP)

---

Applicant: BioMarin International Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: 5-year renewal of the marketing authorisation

**Action:** Foadoption of advice to CHMP

### 8.3.4. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/R/0039 (without RMP)

---

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.3.5. Treosulfan - TRECONDI (CAP) - EMEA/H/C/004751/R/0019 (without RMP)

---

Applicant: medac Gesellschaft für klinische Spezialpräparate mbH

PRAC Rapporteur: Julia Pallos

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.3.6. Zanamivir - DECTOVA (CAP) - EMEA/H/C/004102/R/0017 (without RMP)

---

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

## 9. Product related pharmacovigilance inspections

### 9.1. List of planned pharmacovigilance inspections

None

## **9.2. Ongoing or concluded pharmacovigilance inspections**

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

## **9.3. Others**

None

# **10. Other safety issues for discussion requested by the CHMP or the EMA**

## **10.1. Safety related variations of the marketing authorisation**

None

## **10.2. Timing and message content in relation to Member States' safety announcements**

None

## **10.3. Other requests**

None

## **10.4. Scientific Advice**

None

# **11. Other safety issues for discussion requested by the Member States**

## **11.1. Safety related variations of the marketing authorisation**

### **11.1.1. Hydroxyethyl starch (NAP) - DE/H/xxxx/WS/1360, DE/H/xxxx/WS/1452**

Applicant(s): Fresenius Kabi Deutschland GmbH, Fresenius Kabi Polska Sp. Z O.O.

PRAC Lead: Martin Huber

Scope: PRAC consultation on two worksharing variation (WS) procedures (DE/H/xxxx/WS/1360 and DE/H/xxxx/WS/1452) related to the assessment of the final results from two imposed clinical trials (PHOENICS and TETHYS), to the update of the risk management plan (RMP) and product information, as well as to the dissemination of a proposed direct healthcare professional communication (DHPC) in order to fulfil the

conditions for lifting the suspension of marketing authorisations adopted by the Commission on 24 May 2022, on request of Germany

**Action:** For adoption of advice to Member States

## 11.2. Other requests

None

## 12. Organisational, regulatory and methodological matters

### 12.1. Mandate and organisation of the PRAC

#### 12.1.1. PRAC membership

---

**Action:** For information

#### 12.1.2. Vote by proxy

---

None

### 12.2. Coordination with EMA Scientific Committees or CMDh-v

None

### 12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

### 12.4. Cooperation within the EU regulatory network

#### 12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

---

**Action:** For discussion

#### 12.4.2. PRAC strategic review and learning meeting (SRLM) under the Spanish presidency of the European Union (EU) Council – Madrid, Spain, 14 - 15 November 2023 - agenda

---

PRAC lead: Maria del Pilar Rayon, Monica Martinez Redondo

**Action:** For discussion

## 12.5. Cooperation with International Regulators

None

## 12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

## 12.7. PRAC work plan

None

## 12.8. Planning and reporting

### 12.8.1. EU Pharmacovigilance system - quarterly workload measures and performance indicators – Q3 2023 and predictions

---

**Action:** For discussion

### 12.8.2. PRAC workload statistics – Q3 2023

---

**Action:** For discussion

## 12.9. Pharmacovigilance audits and inspections

### 12.9.1. Pharmacovigilance systems and their quality systems

---

None

### 12.9.2. Pharmacovigilance inspections

---

None

### 12.9.3. Pharmacovigilance audits

---

None

## 12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

### 12.10.1. Periodic safety update reports

---

None

### 12.10.2. Granularity and Periodicity Advisory Group (GPAG)

---

PRAC lead: Menno van der Elst, Maia Uusküla

**Action:** For discussion

### 12.10.3. PSURs repository

---

None

### 12.10.4. Union reference date list – consultation on the draft list

---

**Action:** For adoption

### 12.10.5. Periodic safety update reports single assessment (PSUSA) – review of 'other considerations' section in the assessment report – update and proposed way forward

---

PRAC lead(s): Sabine Straus, Martin Huber

**Action:** For discussion

## 12.11. Signal management

### 12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

---

None

## 12.12. Adverse drug reactions reporting and additional reporting

### 12.12.1. Management and reporting of adverse reactions to medicinal products

---

None

### 12.12.2. Additional monitoring

---

None

### 12.12.3. List of products under additional monitoring – consultation on the draft list

---

**Action:** For adoption

## **12.13. EudraVigilance database**

### **12.13.1. Activities related to the confirmation of full functionality**

---

None

## **12.14. Risk management plans and effectiveness of risk minimisations**

### **12.14.1. Risk management systems**

---

None

### **12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations**

---

None

## **12.15. Post-authorisation safety studies (PASS)**

### **12.15.1. Post-authorisation Safety Studies – imposed PASS**

---

None

### **12.15.2. Post-authorisation Safety Studies – non-imposed PASS**

---

None

## **12.16. Community procedures**

### **12.16.1. Referral procedures for safety reasons**

---

None

## **12.17. Renewals, conditional renewals, annual reassessments**

None

## **12.18. Risk communication and transparency**

### **12.18.1. Public participation in pharmacovigilance**

---

None

### 12.18.2. Safety communication

---

None

## 12.19. Continuous pharmacovigilance

### 12.19.1. Incident management

---

None

## 12.20. Impact of pharmacovigilance activities

None

## 12.21. Others

### 12.21.1. Good Pharmacovigilance Practice (GVP) – end-of-year update for 2023 and planning for 2024

---

PRAC lead: Sabine Straus

**Action:** For discussion

### 12.21.2. Presentation of draft reflection paper on 'Use of real-world data to generate real-world evidence in non-interventional studies'

---

**Action:** For discussion

## 13. Any other business

Next meeting on: 27-30 November 2023

## 14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

### **EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures**

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:

[http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general\\_content\\_000150.jsp&mid=WC0b01ac05800240d0](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0)

### **Signals assessment and prioritisation**

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

### **Risk Management Plans (RMPs)**

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.

RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

### **Assessment of Periodic Safety Update Reports (PSURs)**

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.

PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

### **Post-authorisation Safety Studies (PASS)**

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

### **Product related pharmacovigilance inspections**

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

For a list of acronyms and abbreviations, see:

[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in](#)



[Pharmacovigilance Risk Assessment Committee \(PRAC\)](#)

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)